Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2013 / Cilt: 59 - Sayı: 4

Investigation of the effects of leptin on the cardiovascular system in patients with systemic sclerosis

Sistemik skleroz’lu hastalarda leptinin kardiyovasküler sistem üzerine etkilerinin araştırılması

Pages
319–324
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Decreased serum leptin levels and increased mean heart rate in patients with systemic sclerosis may be the result of increased sympathetic tone.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cardiac involvement in systemic sclerosis can be seen, and often remains silent.
📊
Key Findings & Data:Materials and Methods: Twenty–seven patients with systemic sclerosisand 28 healthy subjects as a control group were included in the study.
💡
Conclusion & Impact:Conclusion: Decreased serum leptin levels and increased mean heart rate in patients with systemic sclerosis may be the result of increased sympathetic tone.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Cardiac involvement in systemic sclerosis can be seen, and often remains silent. Leptin, which is often associated with hypertension and regulation of sympathetic tone, has been reported to contribute to the development of atherosclerosis, endothelial dysfunction and thrombosis by acting directly. The aim of this study was to investigate the effects of leptin on the cardiovascular system in patients with systemic sclerosis. Materials and Methods: Twenty–seven patients with systemic sclerosisand 28 healthy subjects as a control group were included in the study. Clinical and laboratory parameters, 24-hour Holter ECG and ambulatory blood pressure monitorings were recorded and serum leptin levels were measured in all subjects. Results: Mean leptin levels were lower in patients with systemic sclerosis than in controls. In 24-hour ambulatory blood pressure Holter recordings, the mean systolic and diastolic blood pressure, daytime systolic and diastolic blood pressure, systolic and diastolic blood pressure values at night were lower in patients when compared with controls. There was no relationship between leptin and heart rate variability parameters. A positive correlation was found between leptin levels and 24-hour ambulatory blood pressure parameters. Conclusion: Decreased serum leptin levels and increased mean heart rate in patients with systemic sclerosis may be the result of increased sympathetic tone.

Özet

Amaç: Sistemik sklerozda kardiyak tutulum görülebilmekte ve çoğunluklada sessiz seyretmektedir. Leptin sıklıkla hipertansiyon ve sempatik tonusun düzenlenmesi ile ilişkilidir ve leptin’in direkt etki ile ateroskleroz, endotel fonksiyon bozukluğu ve tromboz gelişiminde katkısı olduğu rapor edilmiştir.Bu çalışmanın amacı sistemik sklerozlu hastalarda leptinin kardiyovasküler sistem üzerine etkilerini araştırmaktır. Gereç ve Yöntem: Çalışmaya 27 sistemik skleroz’lu hasta ile kontrol grubu olarak 28 sağlıklı birey alındı. Tüm bireylerin klinik ve laboratuar parametreleri,24 saatlik Holter EKG ve ambulatuvar kan basıncı monitorizasyonu kaydedildi ve serum leptin düzeyleri ölçüldü. Bulgular: Sistemik skleroz’lu hastalarda ortalama leptin seviyeleri daha düşükbulundu. Yirmi dört saatlik ambulatuvar tansiyon holter kayıtlarında ortalama sistolik ve diyastolik kan basıncı, gündüz sistolik ve diyastolik kan basıncı, gecesistolik ve diyastolik kan basıncı değerleri kontrol grubuna kıyasla sistemikskleroz’lu hastalarda daha düşük bulundu. Leptin ile kalp hızı değişkenliği parametreleri arasında ilişki saptanmadı. Leptin ile 24 saatlik ambulatuvar kan basıncı parametreleri arasında pozitif korelasyon saptandı. Sonuç: Sistemik skleroz’lu hastalarda azalmış serum leptin seviyeleri ve artmışortalama kalp hızı artmış sempatik aktivitenin sonuçları olabilir.

🔖

Cite This Article

NAS, K., İSLAMOĞLU, Y., BATMAZ, I., TEKBAŞ, E., TAHTASIZ, M., YÜKSEL, H., BUDULGAN, M., ARITÜRK, Z. A. (2022). Investigation of the effects of leptin on the cardiovascular system in patients with systemic sclerosis. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 59 - Sayı: 4, 319–324. https://ajindex.com/articles/654930

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Toth MJ, Gottlieb SS, Fisher ML, Ryan AS, Nicklas BJ, Poehlman ET. Plasma leptin concentrations and energy expenditure in heart failure patients. Metabolism 1997;46:450-3
  2. Sinha MK. Human leptin: the hormone of adipose tissue. Eur J Endocrinol 1997;136:461-4
  3. Blum WF Englaro P Hanitsch S, Juul A, Hertel NT, Müller J, et al. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997;82:2904-10
  4. Morash B, Li A, Murphy PR, Wilkinson M, Ur E. Leptin gene expression in the brain and pituitary gla. Endocrinology 1999;140:5995-8
  5. Spitzweg C, Heufelder AE. More clues from fat mice: leptin acts as an opponent of the hypothalamic neuropeptide Y system. Eur J Endocrinol 1997;136:590-1
  6. Lee FY, Li Y, Yang EK, Yang SQ, Lin HZ, Trush MA, et al. Phenotypic abnormalities in macrophages from leptin-deficient, obese m. Am J Physiol 1999;276:386-94
  7. Bouloumié A, Drexler HC, Lafontan M, Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998;83:1059-66
  8. Iwaniec UT, Heaney RP Cullen DM, Yee JA. Leptin increases the number of mineralized bone nodules in vitro. J Bone Miner Res 1998;13:2-12
  9. Denton CP Black CM. Scleroderma--clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90
  10. Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis 2008;66:198-202
  11. Rankin AC. Arrhythmias in systemic sclerosis and related disorders. Card Electrophysiol Rev 2002;6:152-4
  12. Karabay CY, Karaahmet T, Tigen K. Cardiovascular involvement in patients with systemic sclerosis: insights from electromechanical characteristics of the heart. Anadolu Kardiyol Derg 2011;11: 643-7
  13. Ferda Özdemir. Enflamatuvar Romatizmal Hastalıklarda Semptomlar, Bulgular ve Sistemik Sorunlar. Türk Fiz Tıp Rehab Derg 1999;2(Suppl 1):6-23
  14. Dimitroulas T, Giannakoulas G, Karvounis H, Sfetsios T, Koliakos G, Parcharidis G, et al. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 2007;14:135-7
  15. Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology 2008;47:972-5
  16. Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, et al. Asymmetrical dimethylarginine in systemic sclerosis- related pulmonary arterial hypertension. Rheumat